Benzinga | Aug 19, 2021 09:12AM EDT

SVB Leerink Initiates Coverage On Amryt Pharma with Outperform Rating, Announces Price Target of $22

SVB Leerink analyst Mani Foroohar initiates coverage on Amryt Pharma (NASDAQ:AMYT) with a Outperform rating and announces Price Target of $22.